Thank you, and thank you for the opportunity to present today. I'm glad I get the chance to share with you the journey of BioHarvest and the prospects of the company. I'm reminding you that we are a publicly traded company on Nasdaq with the symbol BHST. Just giving you the chance to quickly read our forward-looking statements. With that, I would like to start with what's really been important with BioHarvest is the real assets of BioHarvest are within the team. I'm blessed to have a very experienced team of executives that have been with the company for a significant amount of time. Some of them, like Dr. Yochi Hagay, the co-founder, since inception. Average would be about 10 years with BioHarvest. The team, as I said earlier, has vast experience in multi-discipline from biology, finance, manufacturing, sales, business development, as well as consumer goods. BioHarvest is a global leader in plant cell biology. What we came to the world to do is industrialize plant cell culture, which has been a science for a long time, maybe over 100 years, but really hasn't reached the scale required for it to become an industry to produce plant-based natural molecules. We have built a platform that allows us to produce plant-based material, molecules, compounds, without growing the plant itself. The focus is on the four industries: nutraceuticals, cosmeceuticals, pharma, and the nutrition sectors. We are a CDMO, a contract development and manufacturing organization. We're a biotech company serving all those four industries. We have already garnished four partnerships with significant companies, covering multi different molecules, covering all those sectors that I mentioned earlier. We have been able to produce, so far, a product that we commercialized ourselves as a way to prove our platform technology, as a way to validate the power of our platform technology, which we call Botanical Synthesis. We have 15 patents. Cumulatively, we have sold $100 million of that particular compound called VINIA. Last year, we did about $35 million of revenue, with over $2 million of which were in the CDMO part. We view ourselves as a strategic partner, and that's why instead of contract development and manufacturing organization, we like to call ourselves a strategic partner development and manufacturing organization. What I plan to share with you is what our business model is, the platform, the infrastructure that we've put in place from a manufacturing perspective, our AI program, and scale-up, and provide you with the guidance for the remainder of 2026 and beyond. What's common between all those four industries that I mentioned earlier is that they are looking at natural-based molecules, which is a very fast-growing market opportunity. They want those molecules to have the nature of being proprietary, which means that they can patent them. They want them to be efficacious. They want them to be based on a sustainable technology. They want the economics to work. As I said earlier, they want the naturality. But nature has never been an industrial supply chain for molecules. It is a source of food. It's a source of many other things, but not an industrial supply chain when it comes to plant-based molecules. What's needed to be able to overcome the supply risk, the inconsistency of nature, the climate land changes, the genetic mutations, the purity, and the scarcity is an environment which is controlled. It's a controlled industrial biology. The bottleneck is not demand. It's that reliable supply. BioHarvest brought in the science of programmable plant biology. It's this ability to create cell banks, which we call precision botanics, without any agriculture. We do not grow any plant. We take the plant only once. Once we have the cell banks, the ability to propagate those cells in large-scale bioreactors, to be able to have products at a large scale to provide them to our customers. In the case of VINIA, which is our first product that validates this technology, we sell directly to consumer. In other words, or in other way, the Botanical Synthesis platform technology works in the following manner, as you can see on the slide. It's performed once, the first part, which is meeting the plant. We take the plant only once, we meet it only once, from which we isolate the plant cells that include the compounds or the molecules we're interested in. That process is the programmable biology process. By the way, this is not GMO. We do not do any genetic modification. We do not do any engineering of any sort or form of genetics. We just have the ability to provide very unique conditions for those cells to grow under certain stressful conditions that will ultimately elicit or manifest the molecules that we're interested in. They need to express only the molecules we're interested in, and that's how we program the environment to provide for that purpose. Once we have the cell bank, which then completes the first and only once performed stage per any particular plant, we then get into the perpetual process, which is in a three-week cycle. We get those cells to propagate inside bioreactors from small scale all the way to large scale bioreactors. Ultimately, we get a mud that includes those cells, and those cells get dried, and we get a powder from which we can then, downstream, provide that powder in different forms, be it integrated inside any food product or in a capsule, encapsulated in a capsule that can be sold directly to the consumer or in any other different way. Benefits of the Botanical Synthesis technology, as I mentioned earlier, is the scalability, predictability, and sustainability. The cost of goods are lower, the potency of the molecules, we're not just copying nature, but we are enhancing nature. We magnify the concentration of the molecules that are most active and a desired one, while reducing or eliminating the molecules we have no desire. For example, in the case of the product we've been selling successfully called VINIA, which is based on red grape cells. In one capsule of 400 mg, you get the power of 1,000 grapes without any sugar, or the equivalent of one bottle of red wine without any alcohol or sugar. The bioavailability of natural-based molecules is significantly higher than anything synthetic. Of course, as I mentioned earlier, we have the ability to control the consistency and the reproducibility of the compound that we produce using our bioreactors. Not less important is the patentability. As I mentioned earlier, especially for our CDMO customers, the ownership of a proprietary molecule or a proprietary compound that cannot be copied or would be, if anyone else does the same, it would be infringing on the patent that we would assign to that particular customer of ours. As of the last three years, BioHarvest has engaged in a significant investment in AI tools. The AI tools, some of which are being developed in-house, provide us with the ability to predict the conditions in which we need to subject the plants. Therefore, we shorten using, basically, machine learning. We shorten the cycle of development, but also we can monitor the activity during the manufacturing. Therefore, we reduce the chances for contamination or other matters that would actually contribute negatively to the cost of goods. We also have implemented a model, which we call the receptor model, that allows us to guarantee at least that if we are to go and start developing a new compound, that the molecules of that compound can bind to the particular receptor of interest. I am sure everybody knows what receptors now are. GLP-1, for example, which is the basis for the dietary, sorry, the appetite suppression. You have the Mounjaro from Eli Lilly, or Ozempic, are all based on the interaction with the GLP-1 receptor. What we have currently in the pipeline, beside the first product that we, as I said earlier, VINIA, which has this unique molecule called piceid resveratrol. We have other molecules that are in development at different stages. Just covering them quickly, we have the olive-based product with a unique molecule called verbascoside that gets amplified 15x of its original conformation, PGG, part of the pomegranate product. We recently announced not only the development of a complex aromatic molecule coming from a tree that produces a very unique fragrance. It is a $15 billion a year business. We also announced a supply agreement for 2027 and 2028, valued at above $20 million of that particular compound that we are developing, which will eliminate the need for cutting those trees from which those chips come, from where the molecules that generate this kind of fragrance are. We have announced the progress on two molecules that we are developing for Tate & Lyle, one of the largest suppliers in the world of natural sweeteners. We are also engaged in a project based on saffron, where we have the combination of safranal, picrocrocin, and crocin, that not only provide saffron for culinary purpose, but also for dietary supplements and health purpose. By the way, saffron is the most researched compound or plant ever because of its very rich molecules and their health attributes. As I said, compound is progressing across multiple stages of development. Stage one is the stage where we usually charge anywhere between $500,000- $1 million. Stage two, subsequently, $1 million. Stage three is a $1 million. Just to give you an idea of the development revenue that we have the potential and we are generating. Currently, in 2025 and 2026, all revenue on the CDMO is coming from the development, and we expect in 2027 beyond to have not only revenue from development, but also from manufacturing and royalties. The olive, for example, has already completed all stages, and it is ready as well for manufacturing purpose. It is important to mention VINIA as the first product, because I think that is the best validation of the scalability of our technology. We have sold over $100 million of that product. We have invested $100 million in the technology, and VINIA is, as I said earlier, the first validation. The health attributes are the improvement of blood flow with all the benefits that come as a result of the improvement of the blood flow. In the case of VINIA, the particular molecule called piceid resveratrol, which has the mechanism of action of dilating blood vessels, has been increased by a factor of 100. That gives you a feeling for the magnitude or the power of our technology. We want investors to look at BioHarvest with two lens. One is the asset which is called VINIA, as an asset that has been commercialized, continues to generate revenue and growing. The other asset is the CDMO platform, which is the foundation for our business as we develop and manufacturing molecules for other companies. We have guided this 2026 more than doubling the revenue from 2025 to $4 million-$5 million, and we have guided $33 million-$35 million for the D2C model. We sell VINIA over our website, and about 20% of revenue comes from Amazon. This is a good segue into the particular plant or tree that I spoke about, because that announcement was made on August 11th. We have secured a manufacturing and supply agreement of 20 tons for the period of 2027 and 2028, and that supply agreement is estimated between $20 million and $30 million. Not only is a great achievement because we are the first ever to be able to develop such cell culture or such capability for this type of fragrance, but it also opens the floodgate for other high-end, and with similar chemistry type of molecules. You look at the list and the prices of such compounds, and you could see how the potential for BioHarvest and the technology is very promising. Just to start summarizing what I was trying to convey to you is that we have the ability to go into the all four industries with a significant value proposition, be it in the cosmeceuticals, in the nutraceutical business, like we do for saffron, for example. It goes also for the nutraceutical as well as for the nutrition. We have the two molecules for Tate & Lyle for the nutrition. Our revenue is compounded because we start with development, and imagine all the products that are in development, some of them will reach manufacturing. So we get manufacturing revenue, just like in the case of the fragrance. Each one of them can carry a potential of royalty. For example, we have 20% ownership in the fragrancy molecule. We have 25% ownership in the saffron molecule, and so on and so forth. We provide significant value because of the unique technology. Our customers are captive customers because we are the only company that can use this technology at this time to produce. Down the road in the future, for customers that would need to have very large scale, we would license the manufacturing so they can build their own factory and can produce for their own, and we collect royalties. We start from the inflection point, which I invite you to look at, is that we have been able to reach a good scale on the D2C side. We have proven our CDMO capability, and now we have the enough manufacturing base that when you combine it with our AI capabilities, it provide me with a platform for growth. On the manufacturing side, we currently have a facility of 20 tons- 25 tons. We are building a new facility for which we have raised enough cash late last year. We have raised $21 million. So we have what is needed to complete the new manufacturing facility so that we can entertain not only the VINIA growth, but as well as the fragrance and other molecules that will be in manufacturing in the 2028 and beyond time frame. I have mentioned earlier the CDMO revenue projection as well as the D2C. I am reminding you that if I took the D2C aside and I added the manufacturing of VINIA inside the CDMO, our revenue would be projected for 2026, would be $12 million- $14 million, with a consolidated revenue of $37 million- $40 million for the year 2026. With that, I would like to thank you for your time and for your attention, and look forward to hear from you and the questions or any such thing arises. Thank you.